AIxC Holdings plans to exit its digital asset reserve strategy and redirect resources towards developing commercial services in the robotics sector. The company, traded on Nasdaq under the ticker AIXC, is restructuring its business around robotics and AI services. AIxC will be closing positions in digital assets and reallocating freed-up resources for the rental and implementation of robots for clients. A key milestone was the completion of the first paid order on RoboShare, an online marketplace for robot rentals, which was fulfilled on August 15 in Malibu with the participation of six robots. Los Angeles has been chosen as the first launch point, and AIxC plans to expand RoboShare to markets in ten cities. The RoboShare model allows clients to access robots without significant upfront costs, lowering the barrier for companies and event organizers. AIxC will focus on validating demand in Los Angeles, expanding its range of robots, and refining its operational model before entering other cities. The growing base of customer transactions is expected to provide investors with a clear picture of the commercialization of robotics.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.

Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.















Long-end U.S. Treasury yields surged to multi-year highs, pressuring technology, semiconductor, storage, and optical communication stocks and driving a clear cooling in market risk appetite. At the same time, Anthropic’s revenue came in below some bullish expectations, prompting investors to reassess the AI growth narrative; Unitree Robotics officially listed on the STAR Market, extending momentum in robotics and embodied AI; while SpaceX and other commercial space names showed relative resilience. Investors are now focused on tonight’s Federal Reserve minutes for clearer signals on the policy path and broader market sentiment.














Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.